Literature DB >> 29607863

Total hip replacement in sickle cell disorder: A preliminary report of challenges and early outcome of 21 consecutive patients.

A U Katchy1, U E Anyaehie2, C U Nwadinigwe2, G O Eyichukwu2.   

Abstract

OBJECTIVE: The aim of this study is to describe the pattern of presentation osteoarthritic patients with sickle cell disorder (SCD) in our environment, determine the implant sizes taking the peculiar nature of the pathology and our operating environment into consideration, highlight the challenges and technical difficulties encountered during the procedure, measure the functional outcome and observe complications of treatment, recommend ways of improving outcome. PATIENTS AND METHODS: Between November 2008 and November 2012, 29 consecutive primary total hip replacements (THRs) were performed on 21 patients with avascular necrosis of the head of femur secondary to SCD. Patients' evaluation was performed at two different times of follow-up (1 and 5 years, respectively).
RESULTS: Twenty-one patients were available at 1 year as well as 5-year follow-up. The mean preoperative Harris Hip Score was 20.17 ± 11. The mean postoperative Harris Hip Score was 92.25 ± 13 (P < 0.001) at 1 year and 88.75 ± 10 (P < 0.001) at 5 years. Eighteen patients had regional anesthesia while three had general anesthesia. The average cup size used was 49.43 with a range of 46-54. The average liner size was 49.43 with a range of 46-54. The head size used in all patients was 28. The average stem size was 6.57 with a range of 6-8. The offset used in all the patients was standard All the patients had 1-2 screw fixation of the acetabular shell. Four patients had complications as follows: periprosthetic fracture 1, superficial wound infection 1, pulmonary complication 1, and abdominal crisis 1.
CONCLUSION: : THR is a veritable means of treatment of patients with avascular necrosis of the femoral head arising from SCDs. The challenges encountered during the surgery are related to the quality of bone of the affected patient. Arthroplasty Surgeons in our environment must be fully prepared for the challenges by ensuring a preoperative plan that will take care of the technical problems such as recreating femoral canals, wiring of intraoperative fractures as well as treatment of acetabular defects. A detailed planned total hip arthroplasty can be performed in patients with SCD in younger patients with good clinical benefits.

Entities:  

Keywords:  Arthroplasty; challenges; outcome; sickle cell disorder; total hip replacement

Mesh:

Year:  2018        PMID: 29607863     DOI: 10.4103/njcp.njcp_182_17

Source DB:  PubMed          Journal:  Niger J Clin Pract            Impact factor:   0.968


  5 in total

Review 1.  Hypoxia-inducible factor (HIF): how to improve osseointegration in hip arthroplasty secondary to avascular necrosis in sickle cell disease.

Authors:  Akintunde George; Marianne Ellis; Harinderjit Singh Gill
Journal:  EFORT Open Rev       Date:  2019-09-10

2.  Delayed surgical diagnosis and treatment of severe sickle cell arthropathy: The need to raise clinicians' awareness.

Authors:  Olumuyiwa A Bamgbade; Vera Onongaya; Adanna Anomneze-Collins; Demilade A Omoniyi; Patrice Simmonds-Brooks; Renee N Richards
Journal:  J Taibah Univ Med Sci       Date:  2021-05-31

3.  Total Hip Replacement in Sickle Cell Disease Patients with Avascular Necrosis of Head of Femur: A Retrospective Observational Study.

Authors:  Mohammed Lafi Al-Otaibi; Shah Waliullah; Vineet Kumar
Journal:  Indian J Orthop       Date:  2021-03-28       Impact factor: 1.251

4.  Effects of Lumbar Plexus Block Combined with Infiltration Anesthesia on Anesthesia Comfort Scores and Stress Responses in Elderly Patients Undergoing Hip Replacement.

Authors:  Jizheng Zhang; Yi Li; Xiaohua Sun; Wanlu Ren
Journal:  Dis Markers       Date:  2022-08-10       Impact factor: 3.464

Review 5.  Total hip arthroplasty in sickle cell disease: a systematic review.

Authors:  Eustathios Kenanidis; Konstantinos Kapriniotis; Panagiotis Anagnostis; Michael Potoupnis; Panayiotis Christofilopoulos; Eleftherios Tsiridis
Journal:  EFORT Open Rev       Date:  2020-03-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.